Literature DB >> 25853312

Potent and tumor specific: arming bacteria with therapeutic proteins.

Nele Van Dessel1, Charles A Swofford, Neil S Forbes.   

Abstract

Bacteria are perfect vessels for targeted cancer therapy. Conventional chemotherapy is limited by passive diffusion, and systemic administration causes severe side effects. Bacteria can overcome these obstacles by delivering therapeutic proteins specifically to tumors. Bacteria have been modified to produce proteins that directly kill cells, induce apoptosis via signaling pathways, and stimulate the immune system. These three modes of bacterial treatment have all been shown to reduce tumor growth in animal models. Bacteria have also been designed to convert nontoxic prodrugs to active therapeutic compounds. The ease of genetic manipulation enables creation of arrays of bacteria that release many new protein drugs. This versatility will allow targeting of multiple cancer pathways and will establish a platform for individualized cancer medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25853312      PMCID: PMC4423202          DOI: 10.4155/tde.14.113

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  131 in total

1.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Authors:  Anita Chaudhari; Magdy Mahfouz; Arsenio M Fialho; Tohru Yamada; Ana Teresa Granja; Yonghua Zhu; Wataru Hashimoto; Beatrix Schlarb-Ridley; Wonhwa Cho; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Biochemistry       Date:  2007-01-24       Impact factor: 3.162

3.  The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus.

Authors:  S Vandana; M Raje; M V Krishnasastry
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

4.  Antitumor effect of Bifidobacterium infantis in mice.

Authors:  Y Kohwi; K Imai; Z Tamura; Y Hashimoto
Journal:  Gan       Date:  1978-10

5.  Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters.

Authors:  S Nuyts; L Van Mellaert; S Barbé; E Lammertyn; J Theys; W Landuyt; E Bosmans; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

6.  Bacteriolytic therapy can generate a potent immune response against experimental tumors.

Authors:  Nishant Agrawal; Chetan Bettegowda; Ian Cheong; Jean-Francois Geschwind; Charles G Drake; Edward L Hipkiss; Mitsuaki Tatsumi; Long H Dang; Luis A Diaz; Martin Pomper; Mohammad Abusedera; Richard L Wahl; Kenneth W Kinzler; Shibin Zhou; David L Huso; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-07       Impact factor: 11.205

7.  Containment of tumor-colonizing bacteria by host neutrophils.

Authors:  Kathrin Westphal; Sara Leschner; Jadwiga Jablonska; Holger Loessner; Siegfried Weiss
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

8.  Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth.

Authors:  Markus Loeffler; Gaelle Le'Negrate; Maryla Krajewska; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

9.  Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors.

Authors:  Adam T St Jean; Charles A Swofford; Jan T Panteli; Zachary J Brentzel; Neil S Forbes
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

10.  Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.

Authors:  John T Heap; Jan Theys; Muhammad Ehsaan; Aleksandra M Kubiak; Ludwig Dubois; Kim Paesmans; Lieve Van Mellaert; Richard Knox; Sarah A Kuehne; Phillipe Lambin; Nigel P Minton
Journal:  Oncotarget       Date:  2014-04-15
View more
  10 in total

1.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

2.  Homologous Quorum Sensing Regulatory Circuit: A Dual-Input Genetic Controller for Modulating Quorum Sensing-Mediated Protein Expression in E. coli.

Authors:  Pricila Hauk; Kristina Stephens; Chelsea Virgile; Eric VanArsdale; Alex Eli Pottash; John S Schardt; Steven M Jay; Herman O Sintim; William E Bentley
Journal:  ACS Synth Biol       Date:  2020-09-15       Impact factor: 5.110

Review 3.  Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.

Authors:  Meng Gao; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

Review 4.  Carcinogenesis and therapeutics: the microbiota perspective.

Authors:  Matthew C B Tsilimigras; Anthony Fodor; Christian Jobin
Journal:  Nat Microbiol       Date:  2017-02-22       Impact factor: 17.745

Review 5.  Engineering the gut microbiota to treat chronic diseases.

Authors:  Noura S Dosoky; Linda S May-Zhang; Sean S Davies
Journal:  Appl Microbiol Biotechnol       Date:  2020-07-21       Impact factor: 4.813

Review 6.  Anticancer Actions of Azurin and Its Derived Peptide p28.

Authors:  Fan Huang; Qianhui Shu; Zhaojie Qin; Jianglin Tian; Zhengding Su; Yongqi Huang; Meng Gao
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

Review 7.  Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.

Authors:  Shruti S Sawant; Suyash M Patil; Vivek Gupta; Nitesh K Kunda
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

8.  In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy.

Authors:  Chung-Jen Chiang; Yan-Hong Hong
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

9.  A bacterial toxin that cleaves Ras oncoprotein.

Authors:  Marco Biancucci; Karla J F Satchell
Journal:  Oncotarget       Date:  2015-08-07

10.  Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain.

Authors:  Irena Antic; Marco Biancucci; Yueming Zhu; David R Gius; Karla J F Satchell
Journal:  Nat Commun       Date:  2015-06-08       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.